GLP-3 Retatrutide Canada
Retatrutide Research Peptide in Canada
Precision Synthetics Canada supplies Retatrutide (LY3437943) as a white lyophilized powder in sealed 3 mL glass vials for qualified laboratory and analytical research. Orders ship from Vancouver to Canadian addresses, and the selector on this page shows the current vial sizes, prices and stock.
Retatrutide is studied as a triple receptor agonist across the glucagon (GCGR), GIP (GIPR) and GLP-1 (GLP-1R) pathways. It is investigational and is not approved by Health Canada for therapeutic use.
Compound identity and testing
Compound identity
| Compound |
Retatrutide |
| Development code |
LY3437943 |
| CAS number |
2381089-83-2 |
| Molecular formula |
C221H342N46O68 |
| Appearance |
Lyophilized powder, as recorded on our SideChain Analytics COAs |
| Container |
Sealed 3 mL glass vial |
Reports by vial size
SideChain Analytics is our primary testing laboratory, with occasional supplementary testing by Testides, Vanguard Laboratory and Janoshik. Each report keeps its actual issuing laboratory and reported results.
| Vial size |
Current reports |
| Retatrutide 10 mg |
Janoshik identity and purity report, and a Janoshik endotoxin report |
| Retatrutide 20 mg |
SideChain Analytics identity and purity COA, and a SideChain Analytics LAL endotoxin COA |
| Retatrutide 30 mg |
SideChain Analytics mass, purity and identity COA, and a SideChain Analytics endotoxin COA |
Match the lot printed on the vial to its report through the Product COA button on this page or the Certificate of Analysis library.
Research use only. Not for human or veterinary use.
